JMP Securities raised the firm’s price target on AxoGen to $20 from $17 and keeps an Outperform rating on the shares. The company posted its biggest upside surprise in years on both the top and bottom lines and hired Mike Dale, who has 30 years of experience with both private and public entities, to be the new CEO, the analyst tells investors in a research note. The firm is excited by the recent fundamental improvements and the new talent recruitment at AxoGen.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- AxoGen Updates Corporate Presentation for Stakeholders
- Axogen, Inc. Announces New Leadership Appointments
- Is AXGN a Buy, Before Earnings?
- Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
- AxoGen reports inducement grants under Nasdaq listing rule